[Recent advances in the treatment of fulminant hepatitis B].
Yoshiba
Makoto
M
Division of Gastroenterology, Showa University Fujigaoka Hospital.
D000208:Acute Disease; D000998:Antiviral Agents / Q000627:therapeutic use; D002353:Carrier State / Q000628:therapy*; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017583:Hemodiafiltration; D006509:Hepatitis B / Q000150:complications* / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D017114:Liver Failure, Acute / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy*; D016031:Liver Transplantation; D008775:Methylprednisolone / Q000008:administration & dosage; D010951:Plasma Exchange; D011379:Prognosis; D020551:Pulse Therapy, Drug
D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D019259:Lamivudine; C413685:entecavir; D006147:Guanine; D016572:Cyclosporine; D008775:Methylprednisolone